Sorrento Therapeutics Inc (SRNE)

[Andecker]

Hey 1776! Andecker here! When did you return? I left about 1 yr ago but peaking in on occasion but seeing same old poo - would leave once again. Not sure what to think here - can't get much worse. I had hoped we would have put feet to fire of those those brokerage houses that may have traded illegally?!!? The POOF - nothing! My only thought right now is - if SRNE didn't have value / things about to happen for us, wouldn't the good Judge Jones have said long ago, "...OK, we are done here. Nothing left to do or slice up. Secured debtors - here is your 10 cents on the $. Common stock holders - well sorry - no parting fits for you of any sort!" I have a glimmer of hope we come out whole w/out a reverse split.
Cheers! Had myself a Coors Banquet this evening and a Drewrys Lager as I watched my Motor City Kitties beat KC.

[Brandywhitneylady]

Fluff with a capital F.

[youssef]

https://finance.yahoo.com/news/sorrento-therapeutics-announces-positive-phase-130000469.html

[Brandywhitneylady]

Among other things.

[ezyE]

You Special
I got Parkay

[Brandywhitneylady]

Butter us up before the reverse split news…

[Brandywhitneylady]

Yea, the stock is soaring.. Fifteen cents is in sight. More money to fund the great Dr.’s bonuses.

[Here Today]

Here’s your NON-FLUFF from the Judge:

“Virpax slips as court rules in favor of Scilex and Sorrento”

[Here Today]

Virpax slips as court rules in favor of Scilex and Sorrento


Virpax Pharmaceuticals (NASDAQ:VRPX) traded sharply lower Tuesday after announcing that Sorrento Therapeutics (OTCPK:SRNEQ) and its subsidiary Scilex Pharmaceuticals (NASDAQ:SCLX) won a lawsuit against the company.
Sorrento (OTCPK:SRNEQ), which has filed for bankruptcy, and pain-therapy developer Scilex (SCLX) have engaged in a bitter legal dispute with Virpax (VRPX) and its CEO Anthony Mack since 2021.
In a lawsuit in the Delaware Court of Chancery, the plaintiffs alleged that Mack and Virpax (VRPX) breached an agreement that Mack had signed with SRNEQ when he sold Scilex (SCLX) shares. Sorrento (OTCPK:SRNEQ) acquired Scilex (SCLX) in a deal valued at $47.6M in 2016.
Per the terms, Mack agreed to remain as president of Scilex (SCLX) and not commit to another company that rivals Scilex’s (SCLX) pain therapy ZTlido for two years.
According to the lawsuit, Mack and Virpax (VRPX) breached the agreement when the former stepped down from his position at SCLX in 2018 and established Virpax (VRPX).
On Tuesday, Virpax (VRPX) said that the court ruled in favor of the plaintiffs and that the legal proceedings will continue to determine the damages.

[ezyE]

Appreciate the Love
Thank you

[bobbyknobb]

Sloppy post. Sloppy investor.

[Here Today]

HOWYOU DOING?????


Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy??
Agreement underscores Celularity's demonstrated expertise in cell therapy research?

[1776club]

ROTFLMAOKS... thanks, you that guy who said "don't go in there" as the building was falling.

[ezyE]

okay , you can go which you came from .

We ate grown and have our own money .
Thank you .
For your service

[bobbyknobb]

I came here months ago and warned. This is no investment. If you wanna donate. go ahead. but return ain't commin' Dr. a scam.

[1776club]

Might be unless... they are forced into C7. I believe we have at least 4 months before that could get real. Nothing solid until after 123123.
I get beat up for this, but Mpro is the only thing I see that can save the company. China is in trouble in multiple fronts, the invasion of Taiwan is more about their coming election so China will need to throw the population a bone and Mpro could be it. We should see if that flies before December, but will Sorrento be a viable company by then. Wicked game we are playing. As far as PD L1, well Sorrento says Phase III/Pivotal while Lee's Pharma says P1 +II NCT03676959 https://www.leespharm.com/clinical-trials/#.
Gosh, I don't know who to believe. Highly successful Lee's Phara or C11 Sorrento... tough call. Maybe there is a different "N" number which I cannot find.

[Brandywhitneylady]

Hey boys and girls, we need the fluff, we fell below a dime….no surprise. The great Dr continues to destroy this company as he collects his $30,000+ daily salary. Where is that portfolio update? Covi-Stix? Brazil, Mexico, China, the “cure”, burning the shorts?
Anybody still want to defend him? The reverse split will be the final nail.

[1776club]

What about the Scilex bonus shares?
SRNEQ loses control of SCLEX, the BOD is cleansed, Dr. Ji is tossed as COB.

Drug: SP-102 is currently considered worthless but NDA will be applied for, most likely rejected, NEW Corporate will re-evaluate the possibility/probability of success and cost after conference with FDA/NIH contacts and may put a STOP-LOSS on further investment, put it on the shelf, toss it in the can or sell it off if possible - depending on the conditions set in the merger of Semnur Pharmaceuticals, Inc. .

Fold existing products into a different company public or private and use the tax loss.

Scilex will fade away as the name has no value.

So where does that leave Sorrento and the investors (gamblers) after the dust settles. Fair question would be do the SILEX shares get clawed back? Will SRNEQ survive, Korea or China get acceptance of PS-L1 and SRNE gets a little cash with breathing room and then what is the result of Mpro in China (results in 3rd Q 2023...hey, that's now). Not much left in the "possible bowl" after that within less than 3 years.

Why are we here, well Covid, unwise government excesses in spending, a devastated marketplace ripe for short sellers, unwise government excesses in spending and mainly a BOD/CEO with a narcissistic self-assured hubris that was more focused on a $300 Billion company while shot gunning trials than making a profit for its investors and most importantly surviving long enough to do that.

[1776club]

You don't know because you don't have curiosity. Alfred E. Neuman is the fictitious mascot and cover boy of the American humor magazine Mad. His saying was "What Me Worry" for a while and it was changed once to "Yes, me worry!" after the Three Mile Island accident in 1979. SILEX has no patents, is using a generic drug Lidocane, has never developed a novel pharmaceutical of their own and will have to, most likely, redo P3 on SEMDEXA; there is no guarantee that an NDA will be issued.
The only out I see for SRNEQ is Mpro in China as their world is falling apart... but you know that, right? Data is to be released in the 3rd quarter of 2023... we are in the middle of the 3rd Quarter.
Yes, me worry...you bet.

[Au$tin]

I don’t get the reference… maybe before my time? Either way… patience pays grasshoppper

[1776club]

HEY! Nice to know Alfred E. Neuman lives and the intellectually incurious "What, me worry?" philosophy carried through.

[Au$tin]

not worried here! exciting things...

[1776club]

Unknown, could be 30:1. Have to see what the share price is by December... they have to still be alive by then though.

[Brandywhitneylady]

Reverse split, 20-1 or 25-1? That is the question. Also are the class action lawsuits starting? China will not save this POS. Ji will squeeze what he can then it’s over, he can drain the rest of Scilex too. Nothing here for shareholders.

[1776club]

BOB says tons of money coming and a buyback of shares along with a faster path for Ji to reach the $17 Bonus level. Uh-huh, okie dokie, yup, you bet...
There has to be a RS, which Sorrento has done in the past, and most likely has the SEC doc at the ready. So that happens and then what, Ji sells more stock, it is shorted down once again.
The problem I see is that SP-102 has data for a year and has never applied for the NDA; why?
The data is suspect, or so I believe and indications are that another P3 with a different mechanolatry has to be performed. Several years before approval if approval comes. Mpro, P1 in China with results was described on January 9, 2023 at 9:00 AM EST in a release by Sorrento within which they stated "After communication with the regulatory agency, a Phase 3 protocol was submitted to China NMPA. The Phase 3 trial (MPR-COV-301CN) is entitled: “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy and Safety of STI-1558 for Treatment of Mild and Moderate Symptomatic Adults Infected with SARS-CoV-2”. Once cleared by NMPA, the study, which plans to enroll 1200 COVID-19 patients, will be subsequently commenced."
On Jun 26, 2023 Sorrento reported that Top line data is anticipated in the third quarter of this year. If the trial meets its endpoints... it is the second month of the 3rd Quarter. China is a mess and Covid is still an issue so something new to offer the population that would be calming is a real possibility.
In the meantime Sorrento will sell off parts (kidneys, Lungs, blood, ugly stepchildren) that will get them through. Delay is the hope.
We should see something soon one way or the other from China but C11 exit is months away and how they exit is the question.

[Brandywhitneylady]

Sub penny until the great reverse split happens.

[1776club]

Scilex? It is a penny stock. SRNEQ... truly in every sense a penny stock and if things don't change soon a sub-penny stock.

Big day tomorrow (lol), Auction Sale hearing is, Aug 16.

[Brandywhitneylady]

Unfortunately there are a lot of nobody’s. Including the nobody’s that want to buy this soon to be penny stock.

[ezyE]

Good thing there is no one named Nobody
We good to go🤣🤣🤣🤣🤣

[Brandywhitneylady]

Nice post, agree. Nobody will do business with the crafty CEO anymore, him and the BOD all need to go. People on this board need to accept that we were all scammed, and if you think this will be less than a dime soon, then the reverse split, 20, 25-1, you are correct. This POS will not recover.

[Brandywhitneylady]

Nice post, agree. Nobody will do business with the crafty CEO anymore, him and the BOD all need to go. People on this board need to accept that we were all scammed, and if you think this will be less than a dime soon, then the reverse split, 20, 25-1, you are correct. This POS will not recover.

[1776club]

The only way the doors stay open is with a lot of luck from China or Korea and soon. Unfortunately, I do not see that.
How about that SCILEX HOLDING bidding? I am not sure, but it seems no one wants it. No one really knows the statis of SEMDEXA which received Fast Track status from the FDA and 17 months after study completion has not applied for NDA. Having said that, you don't know what you don't know and for this personal piggy bank of the BOD there is little known. Vickers Vantage Corp. 1.6+ billion deal, lol, came in for about $120 million, bet they are happy. They knew more than the SRNE investors...maybe not. BP has connections in the FDA and NIH and I suspect knows the statis of it.
In any event the drone of "The Best is Yet to Come" and BUY, BUY, BUY has faded along with the stock price. This is not HERTZ who had assets and came out of BK in 14 months but since we are in the 7th month of C11 there is some room to hope.
OVYDSO STI-1558...
The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients (1:1, active:placebo) at 25 sites in China. Covid is hitting the fully masked residents weaking Chinas economy as it burns its way through the population.
We (SORRENTO) anticipate top line data in the third quarter of this year (2023). Hey, it is the 3rd Quarter.
Should the Phase 3 trial be successful, we plan to open dialogue with regulatory agencies around the world to discuss paths to approval.

China represents, in many ways, SARS-CoV-2’s final frontier. With its under-vaccinated residents and sparse infection history, the nation harbors “a more susceptible population than really any other large population I can think of,” says Sarah Cobey, a computational epidemiologist at the University of Chicago. Soon, SARS-CoV-2 will infiltrate that group of hosts so thoroughly that it will be nearly impossible to purge again. “Eventually, just like everyone else on Earth, everyone in China should expect to be infected,” says Michael Worobey, an evolutionary virologist at the University of Arizona.

Dim light at the end of the tunnel...and the dim bulbs in the BOD room who got us here.

[Brandywhitneylady]

Sorrento made headlines in May of 2020 when founder Dr. Henry Ji claimed that the company discovered a cure to COVID-19, which caused its stock to soar 243% in a single day. This took the company's market cap from millions to well over a billion.

"We want to emphasize there is a cure. There is a solution that works 100 percent," Ji told Fox News, a statement that was refuted by health care experts. "If we have the neutralizing antibody in your body, you don't need the social distancing. You can open up a society without fear."

Have some more koolaid, while you look at that portfolio.

[Here Today]

https://www.otcmarkets.com/filing/html?id=16824847&guid=DNN-kFHS95CFABh

[Brandywhitneylady]

What’s in their portfolio again? Need some fluff soon, we are heading towards a dime….burn them shorts!

[Brandywhitneylady]

What’s in their portfolio again? Need some fluff soon, we are heading towards a dime….burn them shorts!

[Brandywhitneylady]

More scamming from our fearless leader, the great Dr. more diversions as this company continues to sink, and the inevitable reverse split. Unless you want a “pipeline” update and an estimate of the billions this gem is going to make, I would move on.

[Stewguts]

You seem to be somewhat in the know, could you please explain the purpose of the proposed "short holder dividend" of Scilex shares?

I'm intrigued. TIA.

[youssef]

https://finance.yahoo.com/news/sorrento-issues-faq-response-large-130000573.html

[youssef]

https://finance.yahoo.com/news/sorrento-therapeutics-inc-bankruptcy-court-130000311.html

[dia76ca]

SORRENTO PIPELINE (including majority owned SCILEX pipeline)
Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

COVID-19 Programs
Key Programs (Indication) Phase
COVISTIX™ (diagnostic) FDA EUA
COVIMARK™ (diagnostic) FDA EUA
VIREX (diagnostic) PH III
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
OVYDSO (Olgotrelvir) Ph II (pivotal)
Omicron mRNA Vaccine Preclinical

Immunotherapy
Key Programs (Indication) Phase
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Preclinical
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Solid Tumors) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I
TROP2 ADC* (Solid Tumors) Ph I
Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I
BCMA ADC (Liquid Tumors) Preclinical
Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

Pain
Key Programs (Indication) Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
Gloperba® 1.8% Treatment of Gout (Oral) FDA Approval
SEMDEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Delayed Burst Low Dose Naltrexone) Preclinical
RTX (resiniferatoxin) Epidural injection Ph II
RTX (resiniferatoxin) Intra-articular route Ph II

Lymphatic Delivery
Key Programs (Indication) Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I

[youssef]

https://finance.yahoo.com/news/scilex-holding-company-announces-results-130000363.html

[youssef]

https://finance.yahoo.com/news/scilex-holding-company-generates-record-130000212.html

[HeadsIwin]

Sorrento Therapeutics, Inc.
Mon, June 26, 2023 [img][/img]
(Maybe there still is a demand for Covi-19 treatment in other countries.)

"With the completion of enrollment for this trial, Sorrento has treated almost 1,450 volunteers and patients. Once the data is finalized, Sorrento plans to open discussions with regulatory authorities worldwide to discuss the path required for each particular authority for a full approval of Ovydso."

“We are pleased to see that Ovydso has enrolled quickly for a successful completion of enrollment for the phase 3 pivotal trial in China. We look forward to seeing the final data and to working closely with the NMPA during the review to evaluate this as a potential stand-alone treatment for COVID-19 patients as rapidly as possible,” stated Henry Ji, Ph.D., Chairman and CEO of Sorrento.

The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients (1:1, active:placebo) at 25 sites in China.

During the trial, Ovydso has maintained an excellent safety profile with no Grade 3 toxicities reported.

We anticipate top line data in the third quarter of this year.

If the trial meets its endpoints, we have agreements with the China Health Authority (National Medical Products Administration, or NMPA) for a fast review of the application based on this Phase 3 trial.

Should the Phase 3 trial be successful, we plan to open dialogue with regulatory agencies around the world to discuss paths to approval.

[Brandywhitneylady]

Yes, it is unfortunate for all that believed the untruth put forth by our CEO. My commissions will be more than my shares are worth, so I guess I keep these until they drop to trips. GLTA.

[youssef]

https://finance.yahoo.com/news/sorrento-announces-full-enrollment-pivotal-130000089.html

[HeadsIwin]

I found it in the prospectuses.
Your right on that statement.
It's a ominous situation.
Damn that lawsuit.

[ezyE]

Link fo Bankruptcy
Now show link no more trails?

[Logon26]

All this trails are stopped, no money to push it - BK is very expensive / consultants with $1200 per hours and last month cost was over $600.000 only for consultants and lawyers

Page 7 - Assets only $752.900M - -$1,1B since February
https://www.sec.gov/Archives/edgar/data/850261/000110465923072951/tm2319181d1_ex99-1.htm

[ezyE]

Why don't you sell and go away
If that's the case